協鑫能科(002015.SZ):協鑫電港品牌首批換電站投入運營
格隆匯10月31日丨協鑫能科(002015.SZ)公佈,公司於2021年3月公吿了《協鑫能科電動汽車換電業務發展規劃》,並召開移動能源戰略轉型發佈會,重點發展布局以綠色出行為主的移動能源業務。公司將在能源生產及能源消費兩個重要領域同時發力,為促進"碳中和"目標達成作出貢獻。、
截至2021年10月31日,協鑫電港品牌首批換電站投入運營,其中商用車換電站1座,乘用車換電站4座,分佈於江蘇省、廣東省、湖北省。在建換電站根據項目進度按計劃快速推進,預計年內投運不低於30座換電站,公司將定期披露換電站建成投運情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.